| International Session（Symposium）5(JSGS・JSGE・JGES) |
| Fri. November 6th 9:30 - 12:00 Room 3: Kobe International Exhibition Hall No.2 Building Conference Room 3A |
| Clinical outcomes of neoadjuvant treatment for patients with borderline resectable pancreatic cancer (BRPC) | |||
| Akiko Todaka1, Katsuhiko Uesaka2, Hirofumi Yasui1 | |||
| 1Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 2Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center | |||
|
|||
|
|||
| Background: The appropriate neoadjuvant treatment for BRPC is still controversial, although this strategy has been widely accepted in clinical practice. Methods: We retrospectively reviewed 81 consecutive patients (pts) who received neoadjuvant treatment for BRPC at our institurtion between Jan 2013 and Dec 2019. Neoadjuvant treatments included S-1 and concurrent radiotherapy (50.4Gy/28fr) as neoadjuvant chemoradiotherapy (NCRT), or 4 cycles of FOLFIRINOX or 2 cycles of gemcitabine plus nab-paclitaxel (GnP) as neoadjuvant chemotherapy (NAC). The key selection criteria are as follows: histologically confirmed pancreas adenocarcinoma or adenosquamous cell carcinoma, diagnosed as BRPC by CT, and no serious comorbidities. Results: Of 68 pts met the selection criteria, NCRT and NAC was performed in 25 pts and 43 pts (GnP in 36 pts and FOLFIRINOX in 7 pts), respectively. Patient characteristics in NCRT/NAC were as follows; median age, 68/67 years; BR-A, 92/86%; cN0, 68/81%. Treatment discontinuation was observed only in 6 pts received NAC. No patient couldn’t undergo laparotomy due to toxicity in both treatments. R0 resection rate was 68% (17 pts) in NCRT and 56% (24 pts) in NAC. Among pts performed R0 resection, 47% in NCRT and 25% in NAC had pN0, and postoperative grade 3/4 adverse events were observed in 12% in NCRT and 17% in NAC. Conclusions: Neoadjuvant treatments for BRCP showed a high R0 resection rate with acceptable toxicity profile regardless of treatment method. |
|||
|
Index Term 1: borderline resectable pancreatic cancer Index Term 2: neoadjuvant treatment |
|||
| Page Top | |||